Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $0.37 in the prior trading day, VYNE Therapeutics Inc (NASDAQ: VYNE) closed at $0.39, up 5.86%. In other words, the price has increased by $5.86 from its previous closing price. On the day, 2.79 million shares were traded. VYNE stock price reached its highest trading level at $0.39 during the session, while it also had its lowest trading level at $0.3443.
Ratios:
Our goal is to gain a better understanding of VYNE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.60 and its Current Ratio is at 7.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On November 18, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 15 ’25 when LEPORE PATRICK G bought 15,000 shares for $2.92 per share. The transaction valued at 43,800 led to the insider holds 51,472 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYNE now has a Market Capitalization of 9934144 and an Enterprise Value of -29687856. For the stock, the TTM Price-to-Sale (P/S) ratio is 20.69 while its Price-to-Book (P/B) ratio in mrq is 0.20. Its current Enterprise Value per Revenue stands at -62.369.
Stock Price History:
The Beta on a monthly basis for VYNE is 1.92, which has changed by -0.8202765 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, VYNE has reached a high of $4.30, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is 15.88%, while the 200-Day Moving Average is calculated to be -72.81%.
Shares Statistics:
The stock has traded on average 2.83M shares per day over the past 3-months and 4732030 shares per day over the last 10 days, according to various share statistics. A total of 25.47M shares are outstanding, with a floating share count of 22.45M. Insiders hold about 11.86% of the company’s shares, while institutions hold 27.66% stake in the company. Shares short for VYNE as of 1759190400 were 1125735 with a Short Ratio of 0.40, compared to 1756425600 on 1336204. Therefore, it implies a Short% of Shares Outstanding of 1125735 and a Short% of Float of 4.4499997.
Earnings Estimates
The firm’s stock currently is rated by 2.0 analysts. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.89 and -$0.89 for the fiscal current year, implying an average EPS of -$0.89. EPS for the following year is -$1.1, with 1.0 analysts recommending between -$1.1 and -$1.1.
Revenue Estimates
1 analysts predict $100k in revenue for . The current quarter. It ranges from a high estimate of $100k to a low estimate of $100k. As of . The current estimate, VYNE Therapeutics Inc’s year-ago sales were $121kFor the next quarter, 1 analysts are estimating revenue of $100k. There is a high estimate of $100k for the next quarter, whereas the lowest estimate is $100k.
